Phase II data presented at this year's AASLD meeting
suggest all-oral, interferon-free regimens may be closer to becoming a reality
than had been expected. For example,. Pharmasset Inc. (NASDAQ:VRUS)
reported results from the Phase IIb ELECTRON trial that showed 100% of patients
receiving PSI-7977 plus ribavirin for 12 weeks acheived a sustained virologic
response 12 weeks after the end of treatment (SVR12). Below are selected data
presented at the meeting for HCV candidates that companies are hoping to
position as